Core Viewpoint - Guoke Ion Medical Technology Co., Ltd. has completed its first round of equity financing, raising approximately 800 million RMB, which will be used for the continued research and development of heavy ion and light ion treatment equipment, industrialization promotion, and treatment center layout [1]. Group 1: Company Development - Guoke Ion and its wholly-owned subsidiary, Lanzhou Taiji Ion Technology Co., Ltd., have over 20 years of experience in the tumor treatment equipment industrialization field, relying on 50 years of research in heavy ion physics and medical accelerators from the Chinese Academy of Sciences [4]. - The company developed China's first fully independently owned carbon ion treatment system in 2019, which was put into clinical use in 2020, making China the fourth country globally to master the core technology of heavy ion cancer treatment [4][5]. Group 2: Technological Advancements - Guoke Ion has recently completed the installation and debugging of the world's first light ion combined treatment device, which aims to reduce costs and improve accessibility [6]. - The new device features three treatment rooms, occupies approximately 1,500 square meters, and is significantly lower in system integration, construction scale, and overall investment compared to traditional heavy ion treatment centers, thus lowering the entry barrier for particle therapy [8]. Group 3: Market Insights - The global particle therapy market is projected to reach approximately 1.7 to 1.8 billion USD by 2025, with heavy ion treatment currently representing a small market share but experiencing faster growth [10]. - China is becoming one of the fastest-growing regions for heavy ion treatment centers globally, with an expected increase in operational and under-construction centers leading to a concentrated operational phase around 2026 [12]. Group 4: Business Model - Guoke Ion aims to build an integrated industrial model that covers equipment manufacturing, center co-construction, operation maintenance, and technical services, moving beyond being a simple equipment supplier [14]. - The company proposes a "co-investment, co-construction, and co-sharing" approach to participate in the national layout of heavy ion treatment centers, indicating a shift towards an industrial platform model in a high-investment, high-technology barrier, and clinically dependent sector [15]. Group 5: Future Outlook - The core challenge for heavy ion treatment lies in transforming national-level research capabilities into replicable and deployable clinical systems. The recent 800 million RMB financing indicates that capital is focused on whether the industry model can be successfully executed in terms of cost, delivery, and center expansion [16]. - As domestic equipment continues to be deployed and new centers are gradually operational, heavy ion treatment is entering a critical window for scaling from demonstration to widespread application [16].